Terminated PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT00570674

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

A Phase I/II Trial of Abraxane in Combination With Carboplatin, Erbitux and Intensity Modulated Radiation Therapy (IMRT)for Treatment of Locally Advanced Squamous Cancer of the Head and Neck

Sponsor: Celgene Corporation

Conditions Adenosquamous Cell Carcinoma Basaloid Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Undifferentiated Carcinoma

Interventions Abraxane Carboplatin Erbitux Intensity Modulated Radiation Therapy

Updated 10 times since 2017 Last updated: Oct 10, 2017 Started: Nov 30, 2007 Primary completion: Oct 31, 2013 Completion: Oct 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study did not continue to phase II due to the importance of HPV status as a prognostic factor to guide treatment decisions.

Other terminated trials from Celgene Corporation

More terminations from Celgene Corporation

Listed as NCT00570674, this PHASE1/PHASE2 trial focuses on Adenosquamous Cell Carcinoma and Basaloid Squamous Cell Carcinoma and remains terminated or withdrawn. Sponsored by Celgene Corporation, it has been updated 10 times since 2007, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE1_PHASE2
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2

▶ Show 5 earlier versions

Jun 2018 — Nov 2020 [monthly]

Terminated PHASE1_PHASE2
May 2018 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2
Aug 2017 — May 2018 [monthly]

Terminated PHASE1_PHASE2

Status: Completed → Terminated
Feb 2017 — Aug 2017 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Dana-Farber Cancer Institute

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.